Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Capital Expenditures (2017 - 2023)

CNBX Pharmaceuticals (CNBX) has disclosed Capital Expenditures for 9 consecutive years, with $1196.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Capital Expenditures changed N/A year-over-year to $1196.0, compared with a TTM value of $1196.0 through Aug 2024, changed N/A, and an annual FY2024 reading of $1196.0, changed N/A over the prior year.
  • Capital Expenditures was $1196.0 for Q4 2023 at CNBX Pharmaceuticals, up from $1143.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $72361.0 in Q2 2019 and bottomed at $26.0 in Q3 2020.
  • Average Capital Expenditures over 5 years is $20004.5, with a median of $5100.0 recorded in 2020.
  • Peak annual rise in Capital Expenditures hit 15.95% in 2020, while the deepest fall reached 99.91% in 2020.
  • Year by year, Capital Expenditures stood at $9800.0 in 2019, then tumbled by 90.38% to $943.0 in 2020, then tumbled by 45.6% to $513.0 in 2021, then skyrocketed by 122.81% to $1143.0 in 2022, then rose by 4.64% to $1196.0 in 2023.
  • Business Quant data shows Capital Expenditures for CNBX at $1196.0 in Q4 2023, $1143.0 in Q3 2022, and $513.0 in Q4 2021.